Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.55 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12883097 | 1.00 | HDAC6 (0.55) | HDAC6PRMT5WDR77KDM1AMAPK1 | |
| SCHEMBL16220625 | 0.92 | HDAC6 (0.55) | HDAC6PRMT5WDR77MAPK1MCHR1 | |
| SCHEMBL7787425 | 0.92 | HDAC6 (0.55) | HDAC6PRMT5WDR77MAPK1MCHR1 | |
| SCHEMBL1174506 | 0.79 | HDAC6 (0.61) | HDAC6PRMT5WDR77KDM1A | |
| SCHEMBL7797683 | 0.79 | KMT2A (0.60) | HDAC6PRMT5WDR77KDM1AMAPK1 | |
| SCHEMBL1175185 | 0.73 | RAB9A (0.60) | HDAC6MAPK1ALDH1A1TP53 | |
| SCHEMBL7794886 | 0.72 | HDAC6 (0.62) | HDAC6PRMT5WDR77KDM1AMAPK1 | |
| SCHEMBL1173977 | 0.72 | HDAC6 (1.00) | HDAC6PRMT5WDR77KDM1AMAPK1 | |
| SCHEMBL7801235 | 0.71 | HDAC1 (0.48) | HDAC6ALDH1A1 | |
| SCHEMBL7795317 | 0.71 | HDAC1 (0.48) | HDAC6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329836-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2010151317-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329836-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC5, HDAC1 | HDAC6 1/4885PRMT5 821/4885WDR77 1675/4885 |
| US-20110046157-A1 | Substituted hydroxamic acids and uses thereof | HDAC6, HDAC5, HDAC1 | HDAC6 1/4885PRMT5 821/4885WDR77 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.